查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1594476

神經病變疼痛治療​​市場：按類型、治療方法、適應症、分佈、最終用戶 - 全球預測 2025-2030

Neuropathic Pain Drug Market by Type (Phantom Limb Pain, Post Herpetic Neuralgia, Post-traumatic Neuropathy), Treatment (Antidepressant Drugs Type, Multimodal Therapy, NSAIDs Type), Indication, Distribution, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

神經病變疼痛治療​​市場2023年估值為118.5億美元，預計到2024年將達到129億美元，複合年成長率為9.93%，預計到2030年將達到230.1億美元。

神經病變疼痛治療​​市場包括旨在治療神經性疼痛的藥品的開發、製造和分銷，神經性疼痛是一種由影響體感神經系統的損傷和疾病引起的複雜病症。糖尿病、癌症和引起神經病變疼痛的脊椎損傷等疾病的日益普及推動了對這些藥物的需求。它主要用於醫療和醫療環境，最終用戶包括醫院、診所和家庭護理機構。關鍵的成長要素包括配方技術的進步、醫療保健支出的增加以及對神經病變疾病及其治療的認知的提高。潛在的機會在於個人化醫療的進步、利用生物技術實現更有效的治療以及醫療基礎設施的進步。然而，市場面臨高昂的研發成本、嚴格的法律規範以及當前藥物選擇的副作用等限制。此外，一些患者更喜歡物理療法和針灸藥物等替代療法，因為它們是非侵入性的，這對市場成長構成了障礙。最好的創新領域包括生技藥品和基因療法藥物，它們有望提供更有針對性和更有效的解決方案。尋求與生物技術公司的合作夥伴關係並投資於針對患者特定藥物治療方案的預測模型和人工智慧可以提供競爭優勢。市場競爭非常活躍，不斷的研究和新療法的推出證明了其強大的性質。積極主動研發並適應監管變化的企業才能實現永續成長。總體而言，該市場的成功將取決於組織快速創新的能力，同時遵守監管要求，以滿足神經病變疼痛患者的複雜需求。

主要市場統計
基準年[2023] 118.5億美元
預測年份 [2024] 129億美元
預測年份 [2030] 230.1億美元
複合年成長率（%） 9.93%

市場動態：揭示快速發展的神經病變疼痛治療​​市場的關鍵市場洞察

供需的動態交互作用正在改變神經病變疼痛藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球神經系統疾病和糖尿病神經病變的盛行率不斷上升
    • 更偏好治療神經病變的個人化藥物
    • 由於老年人口的增加，對神經病變疼痛治療​​的需求增加
  • 市場限制因素
    • 產品召回與開發新藥成本上升
  • 市場機會
    • 正在進行的神經病變疼痛治療​​臨床測試
    • 採取措施增加神經病變疼痛專科中心的數量並促進分佈
  • 市場問題
    • 與神經病變疼痛藥物相關的副作用

波特的五力：駕馭神經病變疼痛藥物市場的策略工具

波特的五力框架是了解神經病變疼痛治療​​藥物市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點，避免潛在的挑戰，確保更強大的市場地位。

PESTLE分析：了解神經病變疼痛治療​​市場的外部影響

外部宏觀環境因素在塑造神經病變疼痛治療​​藥物市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解神經病變疼痛治療​​市場的競爭格局

神經病變疼痛治療​​藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：神經病變疼痛治療​​藥物市場供應商的績效評估

FPNV 定位矩陣是評估神經病變疼痛治療​​藥物市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：規劃神經病變疼痛藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對神經病變疼痛治療​​藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1.市場滲透率：對當前市場環境的詳細審查，主要企業的廣泛資料，評估他們在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球神經系統疾病和糖尿病神經病變的盛行率不斷上升
      • 神經病變治療中對個人化藥物的偏好
      • 老年人口的增加增加了對神經病變疼痛治療​​的需求
    • 抑制因素
      • 產品召回和開發新藥高成本
    • 機會
      • 神經病變疼痛治療​​的臨床測試正在進行中
      • 努力增加神經病變和疼痛專科中心的數量並促進分佈
    • 任務
      • 與神經病變疼痛藥物相關的副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章神經病變疼痛治療​​藥物市場：依類型

  • 介紹
  • 幻肢痛
  • 帶狀皰疹後遺症神經痛
  • 神經病變
  • 三叉神經痛

第7章神經病變疼痛治療​​藥物市場：根據治療藥物法

  • 介紹
  • 抗憂鬱症型
    • 血清素去甲腎上腺素
    • 三環抗憂鬱藥物
  • 多模態治療
  • 非類固醇抗發炎藥類型
    • Ibuprofen
    • 萘普生

第8章神經病變疼痛治療​​藥物市場：依適應症分類

  • 介紹
  • 糖尿病神經病變
  • 脊椎狹窄

第9章神經病變疼痛治療​​藥物市場：依分佈

  • 介紹
  • 網路藥房
  • 零售藥局/藥局

第 10 章神經病變疼痛治療​​藥物市場：依最終使用者分類

  • 介紹
  • 診所
  • 醫院

第11章美洲神經病變疼痛治療​​市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太神經病變疼痛治療​​市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲的神經病變疼痛治療​​市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 禮來公司與 Comfo Therapeutics 簽署價值 6.3 億美元的非鴉片類藥物協議，用於治療神經病變疼痛
    • 推出用於神經病變疼痛管理的 AFD-NP 產品
    • 阿克洛斯接受美國國立衛生研究院 (NIH)津貼，繼續研究治療神經病變疼痛的非鴉片類藥物替代品
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • Aptinyx Inc.
  • Assertio Holdings, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Axsome Therapeutics, Inc.
  • Bausch Health Companies Inc.
  • Baxter International Inc.
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • CARA THERAPEUTICS, INC.
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Grunenthal Group
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Scilex Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Trevena Inc.
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-036C5CF3B4DE

The Neuropathic Pain Drug Market was valued at USD 11.85 billion in 2023, expected to reach USD 12.90 billion in 2024, and is projected to grow at a CAGR of 9.93%, to USD 23.01 billion by 2030.

The neuropathic pain drug market encompasses the development, manufacturing, and distribution of pharmaceuticals aimed at treating neuropathic pain, a complex condition caused by damage or disease affecting the somatosensory nervous system. The necessity for these drugs is propelled by the growing prevalence of conditions such as diabetes, cancer, and spinal injuries that contribute to neuropathic pain. They are applied primarily in healthcare and medical settings, with end-users being hospitals, clinics, and homecare setups. Key growth influencers include technological advancements in drug formulation, increased healthcare expenditures, and rising awareness about neuropathic conditions and their drug treatments. Potential opportunities lie in the development of personalized medicine, leveraging biotechnology for more effective treatments, and exploring untapped markets in developing regions with emerging healthcare infrastructures. However, the market faces limitations such as high research and development costs, stringent regulatory frameworks, and side effects of current pharmacological options. Additionally, market growth is challenged by the availability of alternative therapies like physiotherapy and acupuncture, which some patients prefer due to their non-invasive nature. Best areas for innovation include biologics and gene therapy, which hold promise in offering more targeted and effective solutions. Exploring partnerships with biotechnology firms and investing in artificial intelligence for predictive modeling and patient-specific treatment regimens could provide competitive advantages. The neuropathic pain drug market is highly dynamic and competitive, characterized by ongoing research and the introduction of new therapies which indicate its robust nature. Companies that proactively engage in research and development and adapt to regulatory changes are positioned to achieve sustainable growth. Overall, success in this market will likely hinge on an organization's ability to innovate rapidly while maintaining compliance with regulatory requirements, thereby meeting the complex needs of patients suffering from neuropathic pain.

KEY MARKET STATISTICS
Base Year [2023] USD 11.85 billion
Estimated Year [2024] USD 12.90 billion
Forecast Year [2030] USD 23.01 billion
CAGR (%) 9.93%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Neuropathic Pain Drug Market

The Neuropathic Pain Drug Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of neurological disorders and diabetic neuropathy worldwide
    • Significant preference for personalized medicines for neuropathic treatment
    • Increase in the geriatric population raises the demand for neuropathic pain management
  • Market Restraints
    • Product recall and high cost of new drug development
  • Market Opportunities
    • Ongoing clinical trial for neuropathic pain treatment
    • Rising number of specialty neuropathy and pain centers and efforts to boost distribution
  • Market Challenges
    • Side effects associated with neuropathic pain drug

Porter's Five Forces: A Strategic Tool for Navigating the Neuropathic Pain Drug Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Neuropathic Pain Drug Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Neuropathic Pain Drug Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Neuropathic Pain Drug Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Neuropathic Pain Drug Market

A detailed market share analysis in the Neuropathic Pain Drug Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Neuropathic Pain Drug Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Neuropathic Pain Drug Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Neuropathic Pain Drug Market

A strategic analysis of the Neuropathic Pain Drug Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Neuropathic Pain Drug Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., Aptinyx Inc., Assertio Holdings, Inc., Astellas Pharma Inc., AstraZeneca PLC, Axsome Therapeutics, Inc., Bausch Health Companies Inc., Baxter International Inc., Biogen Inc., Bristol-Myers Squibb Company, CARA THERAPEUTICS, INC., Daiichi Sankyo Company, Limited, Eli Lilly and Company, GlaxoSmithKline PLC, Grunenthal Group, Johnson & Johnson Services Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Scilex Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Trevena Inc., and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Neuropathic Pain Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Phantom Limb Pain, Post Herpetic Neuralgia, Post-traumatic Neuropathy, and Trigeminal Neuralgia.
  • Based on Treatment, market is studied across Antidepressant Drugs Type, Multimodal Therapy, and NSAIDs Type. The Antidepressant Drugs Type is further studied across Serotonin Noradrenaline and Tricyclic Antidepressants. The NSAIDs Type is further studied across Ibuprofen and Naproxen.
  • Based on Indication, market is studied across Diabetic Neuropathy and Spinal Stenosis.
  • Based on Distribution, market is studied across Online Pharmacies and Retail Pharmacies & Drug Stores.
  • Based on End User, market is studied across Clinics and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of neurological disorders and diabetic neuropathy worldwide
      • 5.1.1.2. Significant preference for personalized medicines for neuropathic treatment
      • 5.1.1.3. Increase in the geriatric population raises the demand for neuropathic pain management
    • 5.1.2. Restraints
      • 5.1.2.1. Product recall and high cost of new drug development
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing clinical trial for neuropathic pain treatment
      • 5.1.3.2. Rising number of specialty neuropathy and pain centers and efforts to boost distribution
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with neuropathic pain drug
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Neuropathic Pain Drug Market, by Type

  • 6.1. Introduction
  • 6.2. Phantom Limb Pain
  • 6.3. Post Herpetic Neuralgia
  • 6.4. Post-traumatic Neuropathy
  • 6.5. Trigeminal Neuralgia

7. Neuropathic Pain Drug Market, by Treatment

  • 7.1. Introduction
  • 7.2. Antidepressant Drugs Type
    • 7.2.1. Serotonin Noradrenaline
    • 7.2.2. Tricyclic Antidepressants
  • 7.3. Multimodal Therapy
  • 7.4. NSAIDs Type
    • 7.4.1. Ibuprofen
    • 7.4.2. Naproxen

8. Neuropathic Pain Drug Market, by Indication

  • 8.1. Introduction
  • 8.2. Diabetic Neuropathy
  • 8.3. Spinal Stenosis

9. Neuropathic Pain Drug Market, by Distribution

  • 9.1. Introduction
  • 9.2. Online Pharmacies
  • 9.3. Retail Pharmacies & Drug Stores

10. Neuropathic Pain Drug Market, by End User

  • 10.1. Introduction
  • 10.2. Clinics
  • 10.3. Hospitals

11. Americas Neuropathic Pain Drug Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Neuropathic Pain Drug Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Neuropathic Pain Drug Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Eli Lilly strikes USD 630 million deal with Confo Therapeutics for non-opioid neuropathic pain drug
    • 14.3.2. Launch of AFD-NP Product For Neuropathic Pain Management
    • 14.3.3. Akelos Receives NIH Grant To Continue Research On Nonopioid Alternative For Neuropathic Pain
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Amgen Inc.
  • 4. Aptinyx Inc.
  • 5. Assertio Holdings, Inc.
  • 6. Astellas Pharma Inc.
  • 7. AstraZeneca PLC
  • 8. Axsome Therapeutics, Inc.
  • 9. Bausch Health Companies Inc.
  • 10. Baxter International Inc.
  • 11. Biogen Inc.
  • 12. Bristol-Myers Squibb Company
  • 13. CARA THERAPEUTICS, INC.
  • 14. Daiichi Sankyo Company, Limited
  • 15. Eli Lilly and Company
  • 16. GlaxoSmithKline PLC
  • 17. Grunenthal Group
  • 18. Johnson & Johnson Services Inc.
  • 19. Merck & Co., Inc.
  • 20. Novartis AG
  • 21. Pfizer Inc.
  • 22. Regeneron Pharmaceuticals Inc.
  • 23. Scilex Pharmaceuticals
  • 24. Teva Pharmaceutical Industries Ltd.
  • 25. Trevena Inc.
  • 26. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. NEUROPATHIC PAIN DRUG MARKET RESEARCH PROCESS
  • FIGURE 2. NEUROPATHIC PAIN DRUG MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. NEUROPATHIC PAIN DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. NEUROPATHIC PAIN DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NEUROPATHIC PAIN DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NEUROPATHIC PAIN DRUG MARKET DYNAMICS
  • TABLE 7. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PHANTOM LIMB PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST HERPETIC NEURALGIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST-TRAUMATIC NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SEROTONIN NORADRENALINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY MULTIMODAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SPINAL STENOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY RETAIL PHARMACIES & DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 92. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 106. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 113. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 118. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 120. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 127. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 134. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 148. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 155. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 158. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 160. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 162. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 175. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 177. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 182. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 184. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 189. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 191. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 194. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 196. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 198. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 201. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 203. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 205. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 208. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 210. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 212. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 215. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 217. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 219. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 222. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 224. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 226. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 229. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 231. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 233. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 236. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 238. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 240. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 243. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 245. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 247. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 250. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 252. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 254. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 257. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 259. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 261. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 262. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 264. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 266. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 267. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 268. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 271. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 273. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 274. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 275. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 278. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 280. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 282. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 283. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 285. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 286. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 287. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 288. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 289. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 291. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 292. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 293. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 294. SWITZERLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 295. SWITZERLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 296. SWITZERLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 297. SWITZERLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. SWITZERLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 299. SWITZERLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 300. SWITZERLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 301. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 302. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 303. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 304. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 306. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 307. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 308. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 309. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 310. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 311. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 312. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 313. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 314. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 315. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 316. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 317. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 318. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 319. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 320. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 321. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 322. NEUROPATHIC PAIN DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 323. NEUROPATHIC PAIN DRUG MARKET, FPNV POSITIONING MATRIX, 2023